Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 7, 2006, Pages 802-807

  Louw, G E ^a   Warren, R M ^a   Donald, P R ^b   Murray, M B ^c   Bosman, M ^d   Van Helden, P D ^a   Young, D B ^e   Victor, T C ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

pncA; Pyrazinamide; Tuberculosis

Indexed keywords

CYCLINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SENSITIVITY; DRUG TOLERANCE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PYRAZINAMIDE; TUBERCULOSIS;

EID: 33745871145     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Davies A P, Billington O J, McHugh T D, et al. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol 2000; 38: 3686-3688.
2. Wade M M, Volokhov D, Peredelchuk M, et al. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 2004; 49: 89-97.
3. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
4. Somoskovi A, Parsons L M, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164-168.
5. Salfinger M, Crowle A J, Reller L B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 1990; 162:201-207.
6. Zhang Y, Scorpio A, Nikaido H, et al. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bactcriol 1999; 181: 2044-2049.
7. Hirano K, Takahashi M, Kazumi Y, et al. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuberc Lung Dis 1997; 78: 117-122.
8. Lee K W, Lee J M, Jung K S. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci 2001; 16: 537-543.
9. Weyer K, Groenewald P, Zwarenstein M, et al. Tuberculosis drug resistance in the Western Cape. S Afr Med J 1995; 85: 499-504.
10. Weyer K. Survey of tuberculosis drug resistance, 2001-2002, Western Cape, http://www.sahealthinfo.org/tb/tbdrugresistance. htm Cape Town, Western Cape, South Africa: MRC SA Health Info Consortium, 1999-current. Accessed May 2006.
11. South African Tuberculosis Vaccine Initiative. http://www. satvi.uct.ac.za/2006. Cape Town, South Africa: University of Cape Town, SATVI, 2006.
12. Streicher E , Warren R , Kewley C, et al. Genotypic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from rural districts of the Western Cape Province of South Africa. J Clin Microbiol 2004; 42: 891-894.
13. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
14. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 42-49.
15. Mitchison D A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-225
16. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543.
17. World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: WHO, 1997.
18. Mitchison D A. Mechanisms of the action of drugs in the short-course chemotherapy. Bull Int Union Tuberc 1985; 60: 36-40.
19. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. Tubercle 1982; 63: 89-98.
20. Cheng S J, Thibert L, Sanchez T, et al. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000; 44: 528-532.
21. Saravia J C, Appleton S C, Rich M L et al. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-429.